Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 197

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 197
---
         
        0.0%
       
       We account for global intangible low-taxed income as period costs when incurred.We recognize, in the consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $10.7 million as of December 31, 2024. 

116

Adaptive Biotechnologies CorporationNotes to Consolidated Financial Statements (Continued) 

A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands): 

        Balance at December 31, 2021
         
        $
        6,915

        Additions in 2022

        1,202

        Balance at December 31, 2022

        8,117

        Additions in 2023

        1,186

        Balance at December 31, 2023

        9,303

        Additions in 2024

        1,407

        Balance at December 31, 2024
         
        $
        10,710

       During the year ended December 31, 2024, 2023 and 2022, we recognized uncertain tax positions of $1.4 million, $1.2 million and $1.2 million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had no accrued interest or penalties related to uncertain tax positions as of December 31, 2024 and 2023.We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.

17.Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common ShareholdersThe following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2024, 2023 and 2022 (in thousands, except share and per